155 related articles for article (PubMed ID: 10346936)
1. Syntheses of biotinylated alpha-galactosylceramides and their effects on the immune system and CD1 molecules.
Sakai T; Naidenko OV; Iijima H; Kronenberg M; Koezuka Y
J Med Chem; 1999 May; 42(10):1836-41. PubMed ID: 10346936
[TBL] [Abstract][Full Text] [Related]
2. Prevention of injury-induced suppression of T-cell immunity by the CD1d/NKT cell-specific ligand alpha-galactosylceramide.
Tulley JM; Palmer JL; Gamelli RL; Faunce DE
Shock; 2008 Feb; 29(2):269-77. PubMed ID: 17693934
[TBL] [Abstract][Full Text] [Related]
3. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes.
Sharif S; Arreaza GA; Zucker P; Mi QS; Sondhi J; Naidenko OV; Kronenberg M; Koezuka Y; Delovitch TL; Gombert JM; Leite-De-Moraes M; Gouarin C; Zhu R; Hameg A; Nakayama T; Taniguchi M; Lepault F; Lehuen A; Bach JF; Herbelin A
Nat Med; 2001 Sep; 7(9):1057-62. PubMed ID: 11533711
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of NBD-alpha-galactosylceramide and its immunologic properties.
Sakai T; Ehara H; Koezuka Y
Org Lett; 1999 Aug; 1(3):359-61. PubMed ID: 10822576
[TBL] [Abstract][Full Text] [Related]
5. Structure-based discovery of glycolipids for CD1d-mediated NKT cell activation: tuning the adjuvant versus immunosuppression activity.
Fujio M; Wu D; Garcia-Navarro R; Ho DD; Tsuji M; Wong CH
J Am Chem Soc; 2006 Jul; 128(28):9022-3. PubMed ID: 16834361
[TBL] [Abstract][Full Text] [Related]
6. CD1d-restricted NKT cell activation enhanced homeostatic proliferation of CD8+ T cells in a manner dependent on IL-4.
Ueda N; Kuki H; Kamimura D; Sawa S; Seino K; Tashiro T; Fushuku K; Taniguchi M; Hirano T; Murakami M
Int Immunol; 2006 Sep; 18(9):1397-404. PubMed ID: 16914507
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of sphinganine analogues of KRN7000 and OCH.
Ndonye RM; Izmirian DP; Dunn MF; Yu KO; Porcelli SA; Khurana A; Kronenberg M; Richardson SK; Howell AR
J Org Chem; 2005 Dec; 70(25):10260-70. PubMed ID: 16323834
[TBL] [Abstract][Full Text] [Related]
8. Alpha-galactosylceramide modulates the induction of indoleamine 2,3-dioxygenase in antigen presenting cells.
Fallarini S; Paoletti T; Panza L; Lombardi G
Biochem Pharmacol; 2008 Sep; 76(6):738-50. PubMed ID: 18671950
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of 1,2,3-triazole containing analogues of the immunostimulant alpha-GalCer.
Lee T; Cho M; Ko SY; Youn HJ; Baek DJ; Cho WJ; Kang CY; Kim S
J Med Chem; 2007 Feb; 50(3):585-9. PubMed ID: 17266209
[TBL] [Abstract][Full Text] [Related]
10. Cell wall glycosphingolipids of Sphingomonas paucimobilis are CD1d-specific ligands for NKT cells.
Sriram V; Du W; Gervay-Hague J; Brutkiewicz RR
Eur J Immunol; 2005 Jun; 35(6):1692-701. PubMed ID: 15915536
[TBL] [Abstract][Full Text] [Related]
11. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice.
Hong S; Wilson MT; Serizawa I; Wu L; Singh N; Naidenko OV; Miura T; Haba T; Scherer DC; Wei J; Kronenberg M; Koezuka Y; Van Kaer L
Nat Med; 2001 Sep; 7(9):1052-6. PubMed ID: 11533710
[TBL] [Abstract][Full Text] [Related]
12. Glycolipid antigen processing for presentation by CD1d molecules.
Prigozy TI; Naidenko O; Qasba P; Elewaut D; Brossay L; Khurana A; Natori T; Koezuka Y; Kulkarni A; Kronenberg M
Science; 2001 Jan; 291(5504):664-7. PubMed ID: 11158680
[TBL] [Abstract][Full Text] [Related]
13. Hyporesponsiveness to natural killer T-cell ligand alpha-galactosylceramide in cancer-bearing state mediated by CD11b+ Gr-1+ cells producing nitric oxide.
Yanagisawa K; Exley MA; Jiang X; Ohkochi N; Taniguchi M; Seino K
Cancer Res; 2006 Dec; 66(23):11441-6. PubMed ID: 17145891
[TBL] [Abstract][Full Text] [Related]
14. Enhancing effects of (2S,3S,4R)-1-O-(alpha-D-galactopyranosyl)-2-(N-hexacosanoylamino) -1,3,4-octadecanetriol (KRN7000) on antigen-presenting function of antigen-presenting cells and antimetastatic activity of KRN7000-pretreated antigen-presenting cells.
Yamaguchi Y; Motoki K; Ueno H; Maeda K; Kobayashi E; Inoue H; Fukushima H; Koezuka Y
Oncol Res; 1996; 8(10-11):399-407. PubMed ID: 9114432
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of alpha-galactosylceramide (KRN7000) and isoglobotrihexosylceramide (iGb3).
Xia C; Yao Q; Schümann J; Rossy E; Chen W; Zhu L; Zhang W; De Libero G; Wang PG
Bioorg Med Chem Lett; 2006 Apr; 16(8):2195-9. PubMed ID: 16458002
[TBL] [Abstract][Full Text] [Related]
16. Total enantioselective synthesis and in vivo biological evaluation of a novel fluorescent BODIPY alpha-galactosylceramide.
Vo-Hoang Y; Micouin L; Ronet C; Gachelin G; Bonin M
Chembiochem; 2003 Jan; 4(1):27-33. PubMed ID: 12512073
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide.
Huang Y; Chen A; Li X; Chen Z; Zhang W; Song Y; Gurner D; Gardiner D; Basu S; Ho DD; Tsuji M
Vaccine; 2008 Mar; 26(15):1807-16. PubMed ID: 18329757
[TBL] [Abstract][Full Text] [Related]
18. A novel function of Valpha14+CD4+NKT cells: stimulation of IL-12 production by antigen-presenting cells in the innate immune system.
Tomura M; Yu WG; Ahn HJ; Yamashita M; Yang YF; Ono S; Hamaoka T; Kawano T; Taniguchi M; Koezuka Y; Fujiwara H
J Immunol; 1999 Jul; 163(1):93-101. PubMed ID: 10384104
[TBL] [Abstract][Full Text] [Related]
19. The synthesis and in vivo evaluation of 2',2'-difluoro KRN7000.
Leung L; Tomassi C; Van Beneden K; Decruy T; Trappeniers M; Elewaut D; Gao Y; Elliott T; Al-Shamkhani A; Ottensmeier C; Werner JM; Williams A; Van Calenbergh S; Linclau B
ChemMedChem; 2009 Mar; 4(3):329-34. PubMed ID: 19137519
[TBL] [Abstract][Full Text] [Related]
20. A modified alpha-galactosyl ceramide for staining and stimulating natural killer T cells.
Liu Y; Goff RD; Zhou D; Mattner J; Sullivan BA; Khurana A; Cantu C; Ravkov EV; Ibegbu CC; Altman JD; Teyton L; Bendelac A; Savage PB
J Immunol Methods; 2006 May; 312(1-2):34-9. PubMed ID: 16647712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
